Model | No. of parameters | Parameters | TP | TN | FP | FN | RCP(%) | SE(%) | SP(%) |
---|
1 | 11 | All Variables | 1 | 22 | 2 | 4 | 79.3 | 20 | 91.7 |
2 | 10 | -Sex | 2 | 22 | 2 | 3 | 82.8 | 40 | 91.7 |
3 | 9 | -Sex-DCM | 3 | 21 | 3 | 2 | 82.8 | 60 | 87.5 |
4 | 8 | -Sex-DCM -PH | 2 | 22 | 2 | 3 | 82.8 | 40 | 91.7 |
5 | 7 | -Sex-DCM -PH -Captopril | 2 | 18 | 6 | 3 | 69.0 | 40 | 75.0 |
6 | 6 | -Sex-DCM -PH -Captopril -Furosemide | 2 | 20 | 4 | 3 | 75.9 | 40 | 83.3 |
7 | 5 | -Sex-DCM -PH -Captopril -Furosemide -VSD | 3 | 16 | 8 | 2 | 65.5 | 60 | 66.7 |
8 | 4* | -Sex-DCM -PH -Captopril -Furosemide -VSD -ibuprofen | 2 | 21 | 3 | 3 | 79.3 | 40 | 87.5 |
- “- “in the column of parameters refers to “exclude” that specific variable from the model 1, which contain all variables. TP true positive (correctly classified to be ‘positive’); TN true negative (correctly classified to be ‘negative’); FP false positive (incorrectly classified to be ‘positive’); FN false negative (incorrectly classified to be ‘negative’), respectively; RCP rate of correct prediction; SE sensitivity; SP specificity
- All variables include: dose per total body weight, weight, gender, postmenstrual age (PMA), Congestive heart failure (CHF), dilated cardiomyopathy (DCM), pulmonary hypertension (PH), Ventricular septal defect (VSD), with captopril, with furosemide, with ibuprofen
- *the common variables used in population pharmacokinetics were dose per total body weight, weight, PNA, CHF